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SUMMARY 
The inter-laboratory study for quinolones in poultry muscle was performed in accordance with ISO/IEC 
Guide 43-1 and 43-2 and ILAC-G13.  
 
For this inter-laboratory study, three test materials were prepared: 
• A blank material (A); 
• A material containing ciprofloxacin and enrofloxacin, the sum of both being just below the MRL, 
danofloxacin and difloxacin both at levels of about the MRL (B); 
• A material containing ciprofloxacin and enrofloxacin, the sum of both being just above the MRL, 
danofloxacin and difloxacin at levels of approximately 0.5*MRL (C); 
Homogeneity and satisfactory stability of the materials was demonstrated. 
 
Thirty four laboratories were invited to participate in the inter-laboratory study for quinolones in poultry 
muscle of which seventeen laboratories, i.e. 50%, subscribed. Each laboratory received six randomly 
coded samples including one sample of material A, three samples of material B and two samples of 
material C. The laboratories were asked to analyze the samples in duplicate. 
 
Fifteen laboratories managed to submit results that could be included in the evaluation. The majority of 
those laboratories applied a validated and accredited method for the analysis of quinolones in poultry 
muscle.  
Three laboratories used a method that did not include all the quinolones that are registered for 
medication in poultry in the EU.  
 
The laboratories applied different methodologies. Four different sample clean-up procedures can be 
distinguished: 
• Solid Phase Extraction (SPE): using reversed phase  (C18 or OASIS® HLB) or reversed phase 
combined with cation exchange interaction (SDB-RPS); 
• Filtration (0.45 µm) without any further purification; 
• Ultrafiltration (30 kD) without any further purification;  
• Partial evaporation of the solvent followed by dilution without further purification.  
Two detection techniques were applied for the quantitative and confirmatory analysis of quinolones in 
poultry muscle: LC–MS/MS and LC-(UV)-FLU.  
In accordance with the definition of the MRL, all laboratories considered the sum of enrofloxacin and 
ciprofloxacin in classifying the results as either compliant or non-compliant.  
 
Most participating laboratories determined values for CCα and CCß and, hence, the majority already 
complies with the requirements of Commission Decision 2002/657/EC regarding CCα and CCß that 
apply for registered veterinary drugs as from the 1st of August 2007. 
Some laboratories reported values for CCα and CCß below the MRL. This is not in compliance with the 
definition of CCα and CCß for compounds for which a permitted limit is established. For some 
laboratories the reported values for CCα and CCß are not in agreement with the reproducibility of the 
analysis calculated from the reported results in this inter-laboratory study. In both cases, reconsideration 
of the value of CCα and CCß could be necessary.  
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No false positive or false negative results occurred in this inter-laboratory study. 
For all compounds and materials a considerable variation of the reported results is observed. In some 
cases the lowest and the highest value reported differ by a factor 40. In this inter-laboratory study a 
considerable number of results is classified as questionable or unsatisfactory. Those results could not be 
explained based on the applied detection technique. However, it is observed that filtration (0,45 µm) as 
sample preparation technique, without any further purification is not suitable for the analysis of 
quinolones in poultry muscle. 
For each laboratory, the performance with respect to accuracy, reproducibility, false positive and false 
negative results was expressed in a laboratory performance score. Only 60% of the laboratories obtained 
the maximum score. 
 
Based on the results, it is concluded that extra effort in the optimization of analytical methods for the 
analysis of quinolones in poultry muscle is urgently required: 
• Danofloxacin, difloxacin and sarafloxacin should be included in the methods of analysis of 
quinolones by all laboratories, because those compounds are registered for medication in poultry in 
the EU; 
• Reconsideration of numerical values determined for CCα and CCß may be necessary in some cases; 
• An effort should be made regarding the quantitative analysis of all quinolones in poultry muscle 
with respect to the accuracy and the reproducibility. 
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1 INTRODUCTION 
1.1 Inter-laboratory testing 
Inter-laboratory testing is conducted to provide laboratories with a powerful tool to evaluate and 
demonstrate the reliability of the data that is produced. Next to validation and accreditation, inter-
laboratory testing is an important requirement of the EU Additional Measures Directive 93/99/EEC [1] 
and is increasingly important in the new ISO 17025:2005 [2].  
The aim of this inter-laboratory study was to give laboratories the possibility to evaluate or demonstrate 
their competence for the analysis of quinolones in poultry muscle. This study also provided an 
evaluation of the methods applied for quantitative and confirmatory analysis of quinolones. Since this 
study focuses exclusively on the analytical capability of laboratories rather than the correctness of the 
regulatory decision taken on the basis of the analytical results, throughout the report the terms 
"compliant" and "non-compliant" are avoided. Instead the terms "positive" and "negative" are used to 
indicate respectively the presence or absence of the analyte of interest. 
The inter-laboratory study was carried out in accordance with guidelines ISO/IEC 43-1 [3], ISO/IEC 43-
2 [4] and ILAC-G13 [5]. 
1.2 Quinolones 
The discovery of the synthetic antibacterial agent nalidixic acid in 1962 marks the beginning of decades 
of quinolone development for human and veterinary use [6, 7, 8]. Nalidixic acid was discovered as a by-
product of the production of the anti-malaria drug chloroquine. Nalidixic acid was found to be a rapid 
bactericidal agent by inhibition of the bacterial DNA gyrase synthesis [9]. Nalidixic acid is active 
against the majority of Gram-negative bacteria. Unfortunately it is not active against Pseudomonas 
aeruginosa (responsible for causing numerous infections), Gram-positive organisms and anaerobes. In 
addition, the clinical use of nalidixic acid is limited, because administration results in low drug 
concentrations in serum and tissues. Furthermore, resistance to nalidixic acid developed rapidly in 
numerous organisms. Derivatisation products of nalidixic acid, like oxolinic acid represented only 
marginal improvements over nalidixic acid. 
 
In 1976, the development of flumequine, the first fluoroquinolone, offered significant improvement. 
This monofluoroquinolone indicated that the addition of a fluor atom in the molecule improved Gram-
positive activity. In 1978 norfloxacin, a monofluorinated quinolone with a piperazinyl side-chain was 
developed. This fluoroquinolone has a longer half-time, less protein binding and improved Gram-
negative activity compared to the earlier developed compounds. Still the pharmacokinetic profile and 
activity were not adequate for systemic use [10]. 
Very successful and widely used compounds of the fluoroquinolone group are ciprofloxacin, developed 
in 1981 and its counterpart in veterinary use enrofloxacin [11]. These compounds are active against a 
broad spectrum of Gram-positive as well as Gram-negative species, including Pseudomonas 
aeruginosa. Following oral administration, the drug is well distributed through the body with high 
concentrations in most tissues. 
 
Gram-positive staphylococci became a major problem with increasing resistance to antibiotic 
compounds like ß-lactams and macrolides. Also for quinolones resistance in human pathogens was 
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demonstrated [12]. Therefore, the search for new fluoroquinolones continued, aiming for improved 
activity for ß-lactam, macrolide and quinolone resistant strains, and activity against Gram-positive 
staphylococci and anaerobes. This resulted in the development of fourth-generation quinolones. 
1.3 Quinolones in animal health 
The most notable fluoroquinolones used in veterinary medicine worldwide include ciprofloxacin, 
danofloxacin, enrofloxacin, marbofloxacin, norfloxacin and sarafloxacin [9]. Data gathered by The 
World Health Organization indicate that the use of quinolones differs greatly as regards animal species 
and geographical spread.  
For instance, in the EU licensed quinolones for use in poultry are enrofloxacin, difloxacin, 
danofloxacin, oxolinic acid  and sarafloxacin [13]. In Asia also the use of ciprofloxacin, flumequine, 
oxolinic acid and norfloxacin is licensed [14].  
Quinolones have a very broad clinical application in livestock, poultry, fish and domestic animals in the 
treatment and prevention of respiratory, enteric and urinary tract infections [14].  
 
Quinolone resistance has multiple mechanisms and significant clinical impact. Mutations may occur 
rapidly during fluoroquinolone therapy and may be the most significant factor limiting the use of these 
antimicrobials [15]. The toxicity of quinolones is mild at therapeutic doses and generally consists of 
gastrointestinal disturbances such as nausea and diarrhoea. At higher doses the central nervous system is 
affected resulting in dizziness, depression or insomnia [9].  
 
The distribution and metabolism of enrofloxacin was studied in rats [15]. After oral administration 
enrofloxacin was well absorbed. The substance was widely distributed to all tissues with the highest 
concentration in liver and kidney. Elimination was rapid via both urine and faeces. Ciprofloxacin was 
indicated as the major metabolite of enrofloxacin [15]. The occurrence of metabolism of other 
quinolone compounds was not demonstrated. 
1.4 Quinolones in poultry muscle 
According to EU regulations, all substances for veterinary use need to be included in Annexes I, II or III 
of Council Regulation (ECC) No 2377/90 [13]. Quinolones are included in Annex I: pharmacologically 
active veterinary products for which a Maximum Residue Limit (MRL) is established.  Because 
ciprofloxacin is the major metabolite of enrofloxacin, the MRL for enrofloxacin is established as the 
sum of enrofloxacin and ciprofloxacin.  
 
This inter-laboratory study focuses on enrofloxacin (and its metabolite ciprofloxacin), danofloxacin and 
difloxacin (third generation fluoroquinolones) in poultry muscle. For these fluoroquinolones medication 
of poultry is described [12, 14]. The MRL for these compounds in poultry muscle is presented in Table 
1. The structures of these fluoroquinolones are presented in Figure 1.  
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Table 1. MRL in poultry muscle of fluoroquinolones included in the inter-laboratory study [13] 
Compound Marker residue MRL (µg/kg) 
Enrofloxacin Sum of enrofloxacin and ciprofloxacin 100 
Danofloxacin Danofloxacin 200 
Difloxacin Difloxacin 300 
         
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Molecular structure of (a) enrofloxacin, (b) ciprofloxacin, (c) danofloxacin and (d) difloxacin. 
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2 TEST MATERIALS 
2.1 Sample preparation 
Three test materials were prepared containing different amounts of ciprofloxacin (CIP), enrofloxacin 
(ENR), danofloxacin (DAN) and difloxacin (DIF) by adding methanolic solutions of these compounds 
to blank poultry muscle. The materials were homogenised under cryogenic conditions according to 
standard operating procedures. The materials presented in Table 2 were obtained. 
 
Table 2.Target amount of quinolones in the inter-laboratory study test materials  
Material code Target amount of 
ENR+CIP* 
Target amount of 
DAN 
Target amount of 
DIF 
Amount of material (g) 
A Blank Blank Blank 1000 
B Just below MRL ca.  MRL ca. MRL 3000 
C Just above MRL ca. 0.5*MRL ca. 0.5* MRL 2200 
* Contains both ENR and CIP (approximately 2:1). 
2.2 Sample identification 
Materials A, B and C were stored in poly propylene containers containing at least 25 gram of muscle, 
yielding a total of 30 containers of material A, 90 containers of material B and 60 containers of material 
C. For homogeneity and stability testing, 22 randomly chosen containers of material B and C were used. 
The other samples were randomly coded with a code from QUIN/2006/001 through QUIN/2005/180.  
Thirty sample sets consisting of one sample of material A, three samples of material B and two samples 
of material C were randomly prepared as presented in Appendix I. 
2.3 Homogeneity study 
Ten containers of materials B and C were each analyzed in duplicate for ENR, CIP, DAN and DIF to 
determine the homogeneity of the materials. The homogeneity study was carried out according to The 
International Harmonized Protocol for Proficiency Testing of Analytical Laboratories [16] and ISO/DIS 
13528 [17], taking into account the insights discussed by Fearn et al. [18] and Thompson [19]. 
The results of the homogeneity study and their statistical evaluation is presented in Appendices II and 
III for materials B and C respectively. All materials were demonstrated to be sufficiently homogenous 
for use in the inter-laboratory study.  
Simultaneous with the homogeneity study, two samples of material A were analyzed. These analyses 
demonstrated that material A was free of residues of ciprofloxacin, enrofloxacin, danofloxacin, 
difloxacin, flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid and sarafloxacin (< 5 
µg/kg). It was concluded that material A is suited for use as a blank material in the inter-laboratory 
study. 
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2.4 Sample distribution 
Each of the participating laboratories received a randomly assigned laboratory code (lab1 through 
lab17). The sample sets with the corresponding number, consisting of six coded samples, were sent to 
the participating laboratory at the 16th of January. The sample sets were packed in an insulating box, 
containing dry ice and were dispatched to the participants immediately by courier. Due to Customs 
regulations the samples did not arrive at one of the laboratories (lab8). This laboratory was therefore not 
able to participate. Receipt of the samples in good condition (frozen) was confirmed by all other 
laboratories. 
The samples were accompanied by a letter describing the requested analyses, an acknowledgement of 
receipt form and a results form. Furthermore, a reference standard of DAN, including a certificate of 
analysis, was included in the packages. The participants were asked to use this reference standard. 
The laboratories were advised to store the samples at < -20 °C until analysis. A duplicate analysis of 
each sample was requested, resulting in two results for material A, six results for material B and four 
results for material C. The deadline for sending in results was 3rd of March, allowing the participants at 
least six weeks for analysis.  
2.5 Stability 
From the homogeneity data, the amount of quinolone residues in the materials, just after preparation, is 
calculated from the average of the 10 duplicate results.  
The samples for the stability study were stored at -20 °C, corresponding to the advised storage 
conditions. On the 28th of January and the 17th of February, respectively 43 and 63 days after the initial 
analysis, three containers of material B and C were analyzed in duplicate. On the 15th of March, 88 days 
after the initial analysis and after the deadline of the inter-laboratory study, again three containers of 
material B and C were analyzed. For the three points in time, the average of the results was calculated.  
The results of the initial analysis were compared to the results of the analyses after the deadline of the 
study, using a Students t-test [20]. The hypothesis for this test is: 
 
0 0 dH : x = x  
  
where:  0x  = the average of the initial analyses;  
  dx = the average of the analyses at time=d. 
 
The standard deviation of both analyses are considered the same, because the same analytical procedure 
is applied to obtain the results. Therefore the value t is calculated by: 
 
0 d
0 d
x - x
t =
1 1
s +
n n
 
  
where: 0x = the average amount calculated for the initial analyses; 
 dx = the average amount calculated for the analyses at time=d; 
 0n = number of results of the initial analyses; 
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  dn = number of results of the analyses at time=d; 
  s = 
)2nn(
s)1n(s)1n(
d0
2
dd
2
00
-+
-+-
 
 
 where:   s = pooled standard deviation; 
 0n = number of results of the initial analyses; 
  dn = number of results of the analyses at time=d; 
 0s = standard deviation of the initial analyses calculated from the CV% resulting from   
 the validation procedure; 
 ds = standard deviation of the analyses at time=d calculated from the CV% resulting  
 from the validation procedure. 
 
The calculated value t is compared to a critical value (tcrit) derived from a Students-t table with t having 
0 dn + n - 2  degrees of freedom [20]. If t < tcrit it is demonstrated that no significant difference between 
the average amount of the analyses at time=d and the initial analyses at time=0 is found. In this case the 
material is considered stable.  
 
The results and statistical evaluation of the stability test are presented in Appendix IV. It was 
demonstrated that no significant loss of CIP, ENR and DIF occurred during the timescale of the inter-
laboratory study at the chosen storage conditions. For material C, a significant loss of DAN is found. It 
was observed that a different reference standard of DAN was used for the analysis at t=0 compared to 
the analyses at the other points in time, which could influence the quantitative result. Furthermore, 
based on the results at t=43, 63 and 88 days, it is concluded that no significant loss of DAN is found 
from day 43 through day 88. If DAN would be unstable under the chosen conditions, an ongoing 
decrease of the amount of DAN is expected. Based on this and the results of the inter-laboratory study, it 
is concluded that the stability of DAN is satisfactory. 
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3 APPLIED METHODOLOGIES 
The participating laboratories applied different sample preparation procedures and detection techniques 
for the analysis of quinolones in poultry muscle. A schematic overview of the methods applied is 
presented in Appendix V. 
 
The participants extracted the samples in different ways. The majority used an aqueous extraction 
medium like water, trichloro acetic acid (5%) or a phosphate buffer at neutral pH. Other extraction 
media used are acetonitrile at neutral and low pH, acidic ethanol, acidic glycine and a mixture of 
acetonitrile and methanol at low pH. 
 
Four sample clean-up procedures can be distinguished: 
• Nine participants reported that they applied a Solid Phase Extraction (SPE) procedure. Some 
participants applied reversed phase materials, using C18 or OASIS® HLB. In those cases the 
quinolones were eluted using methanol or acetonitrile, both at neutral or low pH. Other participants 
combined reversed phase with cation exchange interaction using SDB-RPS. These participants 
eluted the quinolones using acetonitrile or methanol, both at high pH. 
• Two participants (lab14 and 16) only filtered their extracts using a 0.45 µm filter without any further 
purification. 
• Two participants (lab1 and 4) applied ultrafiltration (30 kD) as a sample clean-up technique. 
• One participant (lab10) concentrated an aliquot of the raw extract by partial evaporation. Afterwards 
the extract was diluted  using a mixture of ethanol, 25 mM phosphoric acid, acetic acid, 
triethylamine and acetonitrile. This participant did not apply any further clean-up. 
 
Two detection techniques are applied for the analysis of quinolones in poultry muscle. Eight of the 
participants used LC–MS/MS. The other seven participants applied LC–Fluorescence, one participant 
(lab2) in combination with UV detection. According to Commission Decision 2002/657/EC [21],  
MS/MS as well as Fluorescence detection are suited for confirmatory analysis of group B substances. 
 
Of the participants that used LC-MS/MS as a detection technique, six used one or more internal 
standards for the quantification of the quinolones. The internal standards used are: 
• Cincophen (2-Phenyl-4-quinolinecarboxylic acid) from Sigma-Aldrich, St. Louis, MO (USA), 
196479. 
• Lomefloxacin from Sigma-Aldrich, L2906. 
• Quinine from Sigma-Aldrich, 145904. 
• d8-Ciprofloxacin from Chemical Synthesis Services, County Armagh, Northern Ireland, UK, QC 
1077. 
• d5-Enrofloxacin from Chemical Synthesis Services, QC 1138. 
• d5-Oxolinic acid from Chemical Synthesis Services, QC 0148. 
•  d5-Norfloxacin.from Witega Laboratorien, Berlin-Adlershof, GE, OP010. 
 
The laboratories that did not analyze for one or more of the quinolones mentioned in the invitation letter 
are presented in Table 3. It is noted that danofloxacin, difloxacin and sarafloxacin are not included by all 
laboratories. These compounds however, are registered for medication in poultry within the EU and a 
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MRL for poultry tissues is established. Therefore, these compounds should be included in a method of 
analysis used in the framework of regulatory control of residues in poultry muscle.  
 
Table 3. Overview of laboratories that did not include all quinolones in the analysis. 
Compound Not included by (lab code) 
Ciprofloxacin*  
Enrofloxacin*  
Danofloxacin* 5 
Difloxacin* 3, 5, 7 
Flumequine  
Marbofloxacin 2, 3, 5, 17 
Nalidixic acid 5, 9, 17 
Norfloxacin 5, 17 
Oxolinic acid*  
Sarafloxacin* 3, 5, 7 
* Compound registered for medication in poultry in the EU. 
 
All laboratories comply with Council Regulation (ECC) No 2377/90 [13] regarding the definition of the 
MRL of enrofloxacin: all the participants considered the sum of enrofloxacin and ciprofloxacin in the 
classification of compliant or non-compliant results. 
 
An overview of the method performance characteristics of the participating laboratories is presented in 
appendix VI. All values are presented as reported by the laboratories without any adjustments. Thirteen 
of the 15 participating laboratories (i.e. 87%) applied a validated method. Twelve of the participating 
laboratories (i.e. 80%) laboratories reported to have their method accredited for the analysis of 
quinolones in poultry muscle.  
Amongst the participating laboratories, four did not report values for CCα. Hence, not all participating 
laboratories are yet ready to report their results as required by Commission Decision 2002/657/EC [21] 
per 1st of August 2007. It is noted that some laboratories (lab5, 7 and 17) report values for CCα and/or 
CCß below the MRL for all quinolones. For DAN laboratory 1 reported a CCα and CCß below the 
MRL.  This is not in compliance with Commission Decision 2002/657/EC [21] considering the 
definition of CCα and CCß for compounds with an MRL.  
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4 STATISTICAL EVALUATION 
The statistical evaluation was carried out according to the International Harmonized Protocol for the 
Proficiency Testing of Analytical Laboratories [16], elaborated by ISO, IUPAC and AOAC and ISO/DIS 
13528 [17] in combination with the insights published by the Analytical Methods Committee [22, 23] 
regarding robust statistics. 
4.1 Calculation of the assigned value 
The assigned value (X) was determined using robust statistics [22, 23, 24]. The advantage of robust 
statistics is that all values are taken into account: outlying observations are retained, but given less 
weight. Furthermore, it is not expected to receive normally distributed data in an inter-laboratory 
proficiency test. When using robust statistics, the data does not have to be normally distributed in 
contrast to conventional outlier elimination methods. 
The robust mean of the reported results of all participants was used as the assigned value. 
4.2 Calculation of the uncertainty of the assigned value 
The uncertainty of the assigned value is calculated to determine the influence of this uncertainty on the 
evaluation. A high uncertainty of the assigned value will lead to a high uncertainty of the calculated 
participants za-scores. If the uncertainty of the assigned value and thus the uncertainty of the za-score is 
high, the evaluation could indicate unsatisfactory method performance without any cause within the 
laboratory. 
In other words, is it legitimate to draw any conclusion regarding the performance of the participating 
laboratories from the calculated assigned value and za-scores? 
The uncertainty of the assigned value (the robust mean) is calculated from the estimate of the standard 
deviation of the assigned value and the number of values used for the calculation of the assigned value: 
 
σˆu =
n
 
  
 where: u =  uncertainty of the assigned value;  
  n =  number of values used to calculate the assigned value;  
    σˆ =  The estimate of the standard deviation of the assigned value resulting from robust  
statistics. 
 
According to ISO/DIS 13528 [17] the uncertainty of the assigned value (u) is negligible and therefore 
does not have to be included in the statistical evaluation if: 
 
pσ3.0u≤  
  
 where: u = The uncertainty of the assigned value; 
  pσ = target standard deviation (§ 4.3). 
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In case the uncertainty of the assigned value does not comply with this criterion, the uncertainty of the 
assigned value should be taken into account when evaluating the performance of the participants 
regarding the accuracy (§ 4.4). 
4.3 Calculation of the target standard deviation 
According to Commission Decision 2002/657/EC [21], the inter-laboratory coefficient of variation for 
the repeated analysis of a reference or fortified material, under reproducibility conditions, shall not 
exceed the level calculated by the Horwitz equation. 
The Horwitz equation, 0.8495Hσ = 0.02c presents a useful and widespread applied relation between the 
expected standard deviation under reproducibility conditions, Hσ and the concentration, c. It expresses 
inter-laboratory precision expected in inter-laboratory trials. Therefore, this relation is suitable for 
calculating the target standard deviation, pσ in inter-laboratory trials. 
Thompson [11] demonstrated that the Horwitz equation is not applicable to the lower concentration 
range (<120 µg/kg) as well as to the higher concentration range (>138 g/kg). Therefore a 
complementary model is suggested: 
 
For analyte concentrations <120 µg/kg: 
Hσ = 0.22c      
 
For analyte concentrations >138 g/kg: 
0.5
Hσ = 0.01c  
  
 where: Hσ = expected standard deviation in inter-laboratory trials; 
  c  = concentration of the analyte. 
  
The target standard deviation, pσ , was determined using the equation for analyte concentrations <120 
µg/kg for CIP, ENR and DAN (in material C) and the Horwitz equation for DAN (in material B) and 
DIF, with c = the assigned value (X) and pHσ = σ . 
4.4 Performance characteristics with regard to the accuracy 
For illustrating the performance of the participating laboratories with regard to the accuracy a za-score is 
calculated. For the evaluation of the performance of the laboratories, the Guidelines of ISO/IEC Guide 
43-1 [3] and ISO/DIS 13528 [17] are applied. According to these guidelines za-scores are classified as 
presented in Table 4.  
 
Table 4: Classification of z-scores 
z ≤ 2 satisfactory 
2 < z < 3 questionable 
z ≥ 3 unsatisfactory 
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When the calculated uncertainty of the assigned value complies with the criterion mentioned in § 4.2, 
the uncertainty is negligible. In this case the accuracy z-score is calculated from: 
 
a
p
x - X
z =
σ
 
  
 where: az = accuracy z-score; 
   x = the average result of the laboratory; 
    X = assigned value; 
pσ = target standard deviation. 
 
However, if the uncertainty of the assigned value does not comply with the criterion mentioned in § 4.2, 
it could influence the evaluation of the laboratories. Therefore this uncertainty is taken into account by 
calculating the accuracy z-score [13]: 
 
a 2 2
p
x - X
z ' =
σ +u
 
  
 where: az ' = accuracy z-score taking into account the uncertainty of the assigned value; 
  x  = mean result of the laboratory; 
  X  = assigned value; 
pσ = target standard deviation; 
u  = uncertainty of the assigned value. 
4.5 Performance characteristics with regard to reproducibility  
In addition to the evaluation of the accuracy, it is useful to inform the participants about the 
reproducibility of the results. In the design of this inter-laboratory study, three blind samples of material 
B and two blind samples of material C were submitted to the participants. Therefore, every laboratory 
reported multiple results for each material. From the results of the blind samples of material B and C the 
repeatability ( rs ) and an estimate of the within-lab-reproducibility ( LRs ) were calculated [24]. 
 
The repeatability standard deviation is calculated from: 
 
p2
d
s
2
i
r
∑
=  
 
  where: rs = repeatability standard deviation; 
  id = difference between the individual values for a pair; 
  p  = number of pairs. 
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An estimate of the within-lab-reproducibility standard deviation is calculated from: 
 
L
2 2
R L rs = (s + s )  
  
 where: 
LR
s  = estimate of the within-lab-reproducibility standard deviation; 
   rs = repeatability standard deviation; 
   
( ) ( )2 2 2p p r
L
p x - x s
s = -
p(p - 1) 2
Σ Σ
 
  
    where: Ls = between sample variance (if Ls <0 this value is assumed to be zero) 
      p  = number of pairs; 
     px = average result of the duplicates; 
     rs  = repeatability standard deviation. 
 
Because the samples are not analyzed under true within-lab reproducibility conditions, the estimate of 
the within-lab reproducibility standard deviation (
LR
s ) will always be lower than the true within-lab 
reproducibility standard deviation.  
To inform a laboratory of its performance for reproducibility, the Horwitz-ratio (HORRAT) is a suitable 
value [25]. In this report, the HORRAT is calculated from the estimate of the within-lab reproducibility, 
because it is not possible to calculate a reproducibility standard deviation from the laboratory data. The 
reproducibility standard deviation ( Rs ) includes inter-laboratory variation and must therefore always be 
higher than the estimate of the within-lab reproducibility (
LR
s ).  
Because the HORRAT value is calculated from 
LR
s instead of Rs , this value is not for evaluation 
purposes but for information only.  
 
The HORRAT is calculated from: 
 
pσ
s
HORRAT L
R
=  
  
 where: HORRAT  = Horwitz ratio; 
LRs = estimate of the within-lab reproducibility standard deviation; 
   pσ = target standard deviation (§ 4.3). 
 
In this formula, a HORRAT value equal to 1.0 indicates that the estimate of the within-lab 
reproducibility is equal to the predicted maximum reproducibility standard deviation resulting from the 
Horwitz equation. However, the latter refers to reproducibility between laboratories and, hence, would 
normally be higher than the within-lab reproducibility. Therefore it is within reason that the HORRAT 
value calculated from the estimate of the within-lab reproducibility, as done in this report, should be 
substantially below 1.0.  
Nonetheless in this report, a HORRAT value is not regarded as a questionable result unless it exceeds 
1.0. 
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Furthermore, from the calculated inter-laboratory standard deviation (
LR
s ) the expected decision limit  
( eCCα ) is calculated: 
 
LR
e
1.64× s × MRL
CCα = MRL+
x
 
  
 where: eCCα  = expected decision limit based on the inter-laboratory study results; 
   MRL = maximum residue limit (µg/kg); 
   
LRs = estimate of the within-lab reproducibility standard deviation; 
   x = the average result of the laboratory (µg/kg). 
 
For this calculation, it is assumed that the relative within-lab reproducibility standard deviation at the 
MRL is equal to the relative within-lab reproducibility standard deviation at x .  The eCCα , calculated 
based on the inter-laboratory study results is compared to the reported CCα.  
4.6 Calculation of laboratory performance scores 
In the evaluation of this proficiency test, a score is calculated to demonstrate the performance of the 
participating laboratories. This score accounts for the accuracy and reproducibility of the results, and the 
occurrence of false positive and false negative results. For each satisfactory result for the accuracy (|za-
score|≤2.0) and for each satisfactory result for the reproducibility (HORRAT ≤1.0), 1 point is earned. 
However, for each compound detected in material A and each compound other than CIP, ENR, DAN 
and DIF in material B and C (false positive results), two points are subtracted. Furthermore, if CIP, 
ENR, DAN or DIF was not detected in samples originating from material B or C, whilst these 
compounds were included in the method (false negative results), two points are subtracted from the 
score. 
The laboratory performance score is calculated by comparing the points attained with the maximum 
score and is expressed as a percentage. 
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5 RESULTS AND DISCUSSION 
Seventeen out of 34 (i.e. 50%) invited laboratories subscribed for the participation in the inter-
laboratory study for quinolones in poultry muscle. Due to Customs regulations, it was not possible to 
ship the samples to one of the laboratories (lab8). Therefore, this laboratory was not able to participate. 
Fourteen laboratories (i.e. 82%) managed to submit valid results before the deadline of the 3rd of March. 
Laboratory 17 reported their results on the 6th of March. This however, is still within the time frame of 
the stability study. Therefore the results of this laboratory were included in the evaluation.  
 
All laboratories analyzed the samples in duplicate. The number of laboratories included in the statistical 
evaluation is 15 for ciprofloxacin and enrofloxacin, 14 for danofloxacin and 12 for difloxacin.  All 
results are presented as reported by the laboratories, without any correction or adjustments. For 
compounds other than ciprofloxacin, enrofloxacin, danofloxacin and difloxacin, only amounts above 5 
µg/kg are taken into account.  
 
None of the laboratories detected any quinolones in the blank material (material A). No false positive 
results occurred.  
5.1 Evaluation of the results of ciprofloxacin 
All laboratories that sent in results included CIP in their analysis. Therefore the evaluation of CIP is 
based on the results of 15 laboratories. Those results as well as the evaluation of CIP results are 
presented in Appendix VII for material B and VIII for material C. 
 
All laboratories detected CIP in the samples originating from material B and C. No false negative results 
occurred.  
 
Laboratory 11 reported very low amounts of CIP for one of their samples (QUIN/2006/041) originating 
from material B. This duplicate result was identified as an outlier and was therefore not included in the 
calculation of the average result for this laboratory. It was however included in the evaluation of 
reproducibility. 
 
For material B the lowest value reported is 5 µg/kg and the highest value is 73 µg/kg. The assigned 
value of CIP in material B is 33.2 µg/kg with an uncertainty of  3.1 µg/kg. The uncertainty of the 
assigned value of CIP in material B exceeds 0.3σp (§4.2). Therefore, for this material, the uncertainty of 
the assigned value is taken into account in the evaluation of the laboratories. The za’-scores and 
HORRAT values for CIP obtained by each laboratory were calculated. The results are presented in 
Appendix VII.  Graphical representations of the za’-scores and HORRAT values are included. 
 
For material C the lowest value reported is 9 µg/kg and the highest value reported is 84.2 µg/kg. The 
assigned value of CIP in material C is 38.1 µg/kg with an uncertainty of  3.2 µg/kg. The uncertainty of 
the assigned value of CIP in material C exceeds 0.3σp (§4.2). Therefore, for this material, the 
uncertainty of the assigned value is taken into account with regard to the evaluation of the laboratories. 
The za’-scores and HORRAT values for CIP obtained by each laboratory were calculated. The results are 
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presented in Appendix VIII. Graphical representations of the za’-scores and HORRAT values are 
included. 
 
With respect to the accuracy, for both materials the results of two laboratories were questionable and the 
results of two other laboratories were unsatisfactory. Differences in accuracy or reproducibility could 
not be attributed to differences in the applied detection technique. Also no effect of the use of an internal 
standard in case of mass spectrometric detection was demonstrated. However, it is observed that both 
laboratories that applied filtration as the only sample preparation technique, without any further 
purification, obtained unsatisfactory results for both materials.  
The number of satisfactory results for accuracy for both materials is presented in Table 5. 
 
The calculation of the HORRAT value results in a value above 1.0 for laboratory 11 for material B. This 
indicates questionable performance with respect to repeatability. This was caused by the low amount of 
CIP found in one of the samples. The number of satisfactory results for reproducibility for both 
materials is presented in Table 5. 
 
Table 5. Number and percentage of satisfactory results for accuracy and reproducibility for 
ciprofloxacin 
Material No. of satisfactory 
results for accuracy 
% of satisfactory 
results for accuracy 
No. of satisfactory  
results for reproducibility 
% of satisfactory 
results for reproducibility 
B 11 of 15 73% 14 of 15 93% 
C 11 of 15 73% 15 of 15  100% 
 
The CCα reported by the laboratories are compared to the reproducibility calculated from the results in 
this inter-laboratory study (§4.5). For laboratories 1 and 4 the reproducibility of the results of CIP in 
material C are higher than is suggested by the reported CCα for this analyte.  
5.2 Evaluation of the results of enrofloxacin 
All laboratories that sent in results included ENR in their analysis. Therefore the evaluation of ENR is 
based on the results of 15 laboratories. The reported results and the results of the evaluation of ENR are 
presented in Appendix IX for material B and X for material C. 
 
All laboratories detected ENR in the samples originating from material B and C. No false negative 
results occurred.  
 
Laboratory 11 reported a very low amount of ENR for one of the duplicates of one sample 
(QUIN/2006/041) originating from material B. This result was identified as an outlier and was therefore 
not included in the calculation of the average result for ENR for this laboratory. It was however included 
in the evaluation of reproducibility. 
 
For material B the lowest value reported is 4.8 µg/kg and the highest value reported is 206 µg/kg. The 
assigned value of ENR in material B is 68.1 µg/kg with an uncertainty of 5.7 µg/kg. The uncertainty of 
the assigned value of ENR in material B exceeds 0.3σp (§4.2). Therefore, for this material, the 
uncertainty of the assigned value is taken into account with regard to the evaluation of the laboratories. 
 RIKILT Report number 2006.003 20
The za’-scores and HORRAT values for ENR obtained by each laboratory were calculated. The results 
are presented in Appendix IX.  Graphical representations of the za’-scores and HORRAT values are 
included. 
 
For material C the lowest value reported is 22 µg/kg and the highest value reported is 281 µg/kg. The 
assigned value of ENR in material C is 81.9 µg/kg with an uncertainty of 5.6 µg/kg. The uncertainty of 
the assigned value of ENR in material C exceeds 0.3σp (§4.2). Therefore, for this material, the 
uncertainty of the assigned value is taken into account in the evaluation of the laboratories. The za’-
scores and HORRAT values for ENR obtained by each laboratory were calculated. The results are 
presented in Appendix X. Graphical representations of the za’-scores and HORRAT values are included. 
 
With respect to the accuracy, for material B, the result of one laboratory was questionable and the results 
of two laboratories were unsatisfactory. For material C, two laboratories obtained questionable results 
and two laboratories obtained unsatisfactory results. Differences in accuracy or reproducibility could not 
be attributed to differences in the applied detection technique. Also no effect of the use of an internal 
standard in case of mass spectrometric detection was demonstrated. However, it is observed that both 
laboratories that applied filtration as the only sample preparation technique, without any further 
purification, obtained questionable or unsatisfactory results for one or both materials. The number of 
satisfactory results for accuracy for both materials is presented in Table 6. 
 
The calculation of the HORRAT value results in a value above 1.0 for laboratory 11, 14 and 16 for 
material B. For material C, only laboratory 16 obtained a HORRAT value above 1.0. This indicates 
questionable performance of the applied method with regard to repeatability. The number of satisfactory 
results for reproducibility for both materials is presented in Table 6. 
 
Table 6. Number and percentage of satisfactory results for accuracy and reproducibility for enrofloxacin 
Material No. of satisfactory 
results for accuracy 
% of satisfactory 
results for accuracy 
No. of satisfactory  
results for reproducibility 
% of satisfactory 
results for reproducibility 
B 12 of 15 80% 12 of 15 80% 
C 11 of 15 73% 14 of 15  93% 
 
The CCα reported by the laboratories are compared to the reproducibility calculated from the results in 
this inter-laboratory study (§4.5). For laboratories 14 and 16 the reproducibility of the results of ENR in 
material B is higher than is suggested by the reported CCα for this analyte. For laboratories 1 and 16 the 
reproducibility of the results of ENR in material C is higher than is suggested by the reported CCα for 
this analyte. 
5.3 Evaluation of the results of the sum of ciprofloxacin and enrofloxacin 
Because the MRL for ENR is defined as the sum of CIP and ENR, also an evaluation of the sum of CIP 
and ENR was carried out. All of the laboratories that sent in results included CIP and ENR in their 
analysis. Therefore the evaluation for CIP+ENR is based on the results of 15 laboratories. The reported 
results and the results of the evaluation of CIP+ENR are presented in Appendix XI for material B and 
XII for material C. 
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Because laboratory 11 reported a very low amount of CIP for one of the sample (QUIN/2006/041) 
originating from material B, this result was not included in the evaluation of the accuracy of CIP+ENR. 
It was however included in the evaluation regarding the reproducibility. 
 
For material B the lowest value reported is 30 µg/kg and the highest value reported is 278 µg/kg. The 
assigned value of CIP+ENR in material B is 101.4 µg/kg with an uncertainty of 7.4 µg/kg. The 
uncertainty of the assigned value of ENR in material C exceeds 0.3σp (§4.2). Therefore, for this 
material, the uncertainty of the assigned value is taken into account in the evaluation of the laboratories. 
The za’-scores and HORRAT values for CIP+ENR obtained by each laboratory were calculated. The 
results are presented in Appendix XI. Graphical representations of the za’-scores and HORRAT values 
are included. 
 
For material C the lowest value reported is 34 µg/kg and the highest value reported is 356 µg/kg. The 
assigned value of CIP+ENR in material C is 122 µg/kg with an uncertainty of 7.3 µg/kg. The 
uncertainty of the assigned value of CIP+ENR in material C is below 0.3σp (§4.2). Therefore, the 
uncertainty of the assigned value is considered to be negligible. The za-scores and HORRAT values for 
CIP+ENR obtained by each laboratory were calculated. The results are presented in Appendix XII.  
Graphical representations of the za-scores and HORRAT values are included. 
 
With respect to the accuracy for material B, the result of one laboratory was questionable and the results 
of two other laboratories were unsatisfactory. For material C, two laboratories obtained unsatisfactory 
results. Differences in accuracy or reproducibility could not be attributed to differences in the applied 
detection technique. Also no effect of the use of an internal standard in case of mass spectrometric 
detection was demonstrated.  
The number of satisfactory results regarding the accuracy for both materials is presented in table 7. 
 
The calculation of the HORRAT value results in a value above 1.0 for laboratory 11 and 16 for material 
B. For material C, only laboratory 16 obtained a HORRAT value above 1.0. This indicates questionable 
performance of the applied method with regard to repeatability. The number of satisfactory results for 
reproducibility for both materials is presented in Table 7. 
 
Table 7. Number and percentage of satisfactory results for accuracy and reproducibility for  
ciprofloxacin + enrofloxacin 
Material No. of satisfactory 
results for accuracy 
% of satisfactory 
results for accuracy 
No. of satisfactory  
results for reproducibility 
% of satisfactory 
results for reproducibility 
B 12 of 15 80% 13 of 15 87% 
C 13 of 15 87% 14 of 15  93% 
5.4 Evaluation of the results of danofloxacin 
Fourteen laboratories included DAN in their analysis. Therefore the evaluation of DAN is based on the 
results of 14 laboratories. Four laboratories indicated that they did not use the reference standard DAN 
that was supplied with the samples. The reported results and the results of the evaluation of DAN are 
presented in Appendix XIII for material B and XIV for material C. 
All laboratories that included DAN in their analysis detected DAN in the samples originating from 
material B and C. No false negative results occurred.  
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Laboratory 11 reported very low amounts of DAN for both duplicates of one sample (QUIN/2006/041) 
originating from material B. These results were indicated as outliers and were therefore not included in 
the calculation of the average result for DAN for this laboratory. They were however included in the 
evaluation of the reproducibility. 
 
For material B the lowest value reported is 18 µg/kg and the highest value reported is 540 µg/kg. The 
assigned value of DAN in material B is 192 µg/kg with an uncertainty of 11 µg/kg. The uncertainty of 
the assigned value of DAN in material B is below 0.3σp (§4.2). Therefore, the uncertainty of the 
assigned value is considered to be negligible. The za-scores and HORRAT values for ENR obtained by 
each laboratory were calculated. The results are presented in Appendix XIII.  Graphical representations 
of the za-scores and HORRAT values are included. 
 
For material C the lowest value reported is 8 µg/kg and the highest value reported is 295 µg/kg. The 
assigned value of DAN in material C is 118 µg/kg with an uncertainty of 9.3 µg/kg. The uncertainty of 
the assigned value of DAN in material C exceeds 0.3σp (§4.2). Therefore, for this material, the 
uncertainty of the assigned value is taken into account in the evaluation of the laboratories. The za’-
scores and HORRAT values for DAN obtained by each laboratory were calculated. The results are 
presented in Appendix XIV. Graphical representations of the za’-scores and HORRAT values are 
included. 
 
With respect to the accuracy, for both materials, the results of three laboratories were unsatisfactory. 
Differences in accuracy or reproducibility could not be attributed to differences in the applied detection 
technique. Also no effect of the use of an internal standard in case of mass spectrometric detection was 
demonstrated.  
Surprisingly, no relation was found between the results and laboratories that did or did not use the 
supplied reference standard for DAN. It is observed that both laboratories that applied filtration as the 
only sample preparation technique, without any further purification, obtained unsatisfactory results for 
both materials.  
The number of satisfactory results regarding the accuracy for both materials is presented in table 8. 
 
The calculation of the HORRAT value results in a value above 1.0 for laboratory 16, 14 and 11 for 
material B. For material C, only laboratory 16 obtained a HORRAT value above 1.0. This indicates 
questionable performance of the applied method with regard to repeatability. The number of satisfactory 
results for reproducibility for both materials is presented in Table 8. 
 
Table 8. Number and percentage of satisfactory results for accuracy and reproducibility for danofloxacin 
Material No. of satisfactory 
results for accuracy 
% of satisfactory 
results for accuracy 
No. of satisfactory  
results for reproducibility 
% of satisfactory 
results for reproducibility 
B 11 of 14 79% 11 of 14 79% 
C 11 of 14 79% 13 of 14 93% 
 
The CCα reported by the laboratories are compared to the reproducibility calculated from the results in 
this inter-laboratory study (§4.5). For laboratory 14 the reproducibility of the results of DAN in both 
materials is higher than is suggested by the reported CCα for this analyte. For laboratory 16 the 
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reproducibility of the result of DAN in material C is higher than is suggested by the reported CCα for 
this analyte.  
5.5 Evaluation of the results of difloxacin 
Twelve laboratories included DIF in their analysis. Therefore the evaluation of DIF is based on the 
results of 12 laboratories. The reported results and the results of the evaluation of DIF are presented in 
Appendix XV for material B and XVI for material C. 
 
All laboratories that included DIF in their analysis detected DIF in the samples originating from 
material B and C. No false negative results occurred.  
 
For material B the lowest value reported is 81 µg/kg and the highest value reported is 612 µg/kg. The 
assigned value of DIF in material B is 299 µg/kg with an uncertainty of 22 µg/kg. The uncertainty of the 
assigned value of DIF in material B is exceeds 0.3σp (§4.2). Therefore, for this material, the uncertainty 
of the assigned value is taken into account in the evaluation of the laboratories. The za’-scores and 
HORRAT values for DIF obtained by each laboratory were calculated. The results are presented in 
Appendix XV.  Graphical representations of the za’-scores and HORRAT values are included. 
 
For material C the lowest value reported is 50 µg/kg and the highest value reported is 362 µg/kg. The 
assigned value of DIF in material C is 188 µg/kg with an uncertainty of 20 µg/kg. The uncertainty of the 
assigned value of DIF in material C exceeds 0.3σp (§4.2). Therefore, for this material, the uncertainty of 
the assigned value is taken into account in the evaluation of the laboratories. The za’-scores and 
HORRAT values for DIF obtained by each laboratory were calculated. The results are presented in 
Appendix XVI. Graphical representations of the za’-scores and HORRAT values are included. 
 
With respect to the accuracy, for both materials, the results of three laboratories were unsatisfactory. 
Differences in accuracy could not be attributed to the applied detection technique. Also no effect of the 
use of an internal standard in case of mass spectrometric detection was observed. The number of 
satisfactory results for accuracy for both materials is presented in Table 9. 
 
The calculation of the HORRAT value results in a value above 1.0 for laboratory 16 and 14 for material 
B. This indicates questionable performance of the applied method for repeatability. For material C no 
HORRAT values above 1.0 were obtained. The number of satisfactory results for reproducibility for 
both materials is presented in Table 9. 
 
Table 9. Number and percentage of satisfactory results for accuracy and reproducibility for difloxacin 
Material No. of satisfactory 
results for accuracy 
% of satisfactory 
results for accuracy 
No. of satisfactory  
results for reproducibility 
% of satisfactory 
results for reproducibility 
B 9 of 12 75% 10 of 12 83% 
C 9 of 12 75% 12 of 12 100% 
 
The CCα reported by the laboratories are compared to the reproducibility calculated from the results in 
this inter-laboratory study (§4.5). For laboratories 12, 14 and 15 the reproducibility of the results of DIF 
in material B is higher than is suggested by the reported CCα for this analyte. For laboratories 4, 12 and 
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14 the reproducibility of the results of DIF in material C is higher than is suggested by the reported CCα 
for this analyte. 
5.6 Laboratory scores 
The performance of each participating laboratory is expressed in a laboratory performance score (§4.6). 
The maximum attainable score is 100%. The laboratory performance score and the maximum attainable 
score per lab are presented in Appendix XVII. 
From the 15 laboratories 9 (i.e. 60%) showed optimal performance for the analysis of quinolones in 
poultry muscle with respect to the accuracy,  repeatability and the occurrence of false positive and false 
negative results.  
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6 CONCLUSION 
Thirty four laboratories were invited to participate in the inter-laboratory study for quinolones in poultry 
muscle, of which seventeen laboratories subscribed.  
Fourteen laboratories reported their results within the given time scale. One laboratory reported their 
results with a delay of three days. All reported results were included in the report without any 
modifications. 
 
Three laboratories did not include all the quinolones that are registered for medication in poultry in the 
EU in their method. In these cases false negative results may occur. All laboratories comply with 
Council Regulation (ECC) No 2377/90 [13] the definition of the MRL of enrofloxacin: all participants 
considered the sum of enrofloxacin and ciprofloxacin in the characterisation of compliant or non-
compliant results.  
 
The majority of participants applied an accredited method for the analysis of quinolones in poultry 
muscle. Three laboratories did not report a value for CCα and CCß. Apparently some laboratories are 
not yet ready to comply with the requirements of Commission Decision 2002/657/EC [21] for registered 
veterinary drugs as per 1st of August 2007. 
Some laboratories reported values for CCα and CCß below the MRL. This is not in accordance with 
Commission Decision 2002/657/EC [21] considering the definition of CCα and CCß for compounds 
with an MRL. 
For some laboratories the values for CCα and CCß are not in agreement with the reproducibility of the 
analysis calculated from the reported results in this inter-laboratory study.  
 
The results of material B and C are summarized in Table 10 and Table 11 respectively. No false negative 
or false positive results occurred. 
 
Table 10. Summary of the results for material B 
Compound No. of satisfactory results 
 
Assigned value (X) 
(µg/kg) 
Uncertainty of X  
(µg/kg) 
No. of labs that 
reported results Accuracy Reproducibility 
CIP 33.2 3.11) 15 11 14 
ENR 68.1 5.71) 15 12 12 
CIP+ENR 101.4 7.41) 15 12 13 
DAN 192 11 14 11 11 
DIF 299 221) 12 9 10 
1) The uncertainty of the assigned value exceeds 0.3σp: the uncertainty of the assigned value is taken into 
account in the evaluation of the laboratories. 
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Table 11. Summary of the results for material C 
Compound No. of satisfactory results 
 
Assigned value 
(X) 
(µg/kg) 
Uncertainty of X  
(µg/kg) 
No. of labs that 
reported results Accuracy Reproducibility 
CIP 38.1 3.21) 15 11 15 
ENR 81.9 5.61) 15 11 14 
CIP+ENR 122 7.3 15 13 14 
DAN 118 9.31) 14 11 13 
DIF 188 201) 12 9 12 
1) The uncertainty of the assigned value exceeds 0.3σp: the uncertainty of the assigned value is taken into 
account in the evaluation of the laboratories. 
 
For all compounds and materials a considerable variation for the reported amount is observed. This 
results in a substantial number of results that are characterised as questionable or unsatisfactory. The 
occurrence of questionable or unsatisfactory results could not be explained by the applied detection 
technique. However, it is observed that filtration as a sample preparation technique, without any further 
purification, is apparently not suitable for the analysis of quinolones in poultry muscle. 
The performance with respect to accuracy, reproducibility, false negative and false positive results was 
expressed in a laboratory performance score for each laboratory. Only 60% of the laboratories obtained 
the maximum score. 
 
Based on the results, it is concluded that extra effort is needed for the optimization of methods of 
analysis for quinolones in poultry muscle: 
• Danofloxacin, difloxacin and sarafloxacin should be included in the method of analysis for 
quinolones, because those compounds are registered for medication in poultry in the EU; 
• Reconsideration of numerical values determined for CCα and CCß may be necessary in some cases; 
• An effort should be made to improve the quantitative analysis of all quinolones in poultry muscle 
with respect to the accuracy and reproducibility. 
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APPENDIX I: Codification of the samples 
 
Sample set Material A Material B Material C 
1 QUIN/2006/092 QUIN/2006/091 QUIN/2006/128 
  QUIN/2006/124 QUIN/2006/116 
  QUIN/2006/126  
2 QUIN/2006/130 QUIN/2006/019 QUIN/2006/177 
  QUIN/2006/131 QUIN/2006/086 
  QUIN/2006/141  
3 QUIN/2006/155 QUIN/2006/107 QUIN/2006/043 
  QUIN/2006/001 QUIN/2006/178 
  QUIN/2006/080  
4 QUIN/2006/170 QUIN/2006/166 QUIN/2006/084 
  QUIN/2006/017 QUIN/2006/040 
  QUIN/2006/061  
5 QUIN/2006/180 QUIN/2006/109 QUIN/2006/068 
  QUIN/2006/133 QUIN/2006/162 
  QUIN/2006/145  
6 QUIN/2006/042 QUIN/2006/137 QUIN/2006/082 
  QUIN/2006/165 QUIN/2006/138 
  QUIN/2006/159  
7 QUIN/2006/123 QUIN/2006/106 QUIN/2006/078 
  QUIN/2006/073 QUIN/2006/049 
  QUIN/2006/066  
8 QUIN/2006/100 QUIN/2006/102 QUIN/2006/054 
  QUIN/2006/115 QUIN/2006/016 
  QUIN/2006/139  
9 QUIN/2006/024 QUIN/2006/006 QUIN/2006/056 
  QUIN/2006/004 QUIN/2006/158 
  QUIN/2006/020  
10 QUIN/2006/029 QUIN/2006/048 QUIN/2006/090 
  QUIN/2006/147 QUIN/2006/026 
  QUIN/2006/119  
11 QUIN/2006/025 QUIN/2006/173 QUIN/2006/052 
  QUIN/2006/012 QUIN/2006/003 
  QUIN/2006/041  
12 QUIN/2006/171 QUIN/2006/063 QUIN/2006/150 
  QUIN/2006/135 QUIN/2006/021 
  QUIN/2006/028  
13 QUIN/2006/104 QUIN/2006/093 QUIN/2006/105 
  QUIN/2006/065 QUIN/2006/179 
  QUIN/2006/053  
14 QUIN/2006/089 QUIN/2006/037 QUIN/2006/161 
  QUIN/2006/044 QUIN/2006/058 
  QUIN/2006/153  
15 QUIN/2006/045 QUIN/2006/014 QUIN/2006/035 
  QUIN/2006/117 QUIN/2006/114 
  QUIN/2006/148  
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APPENDIX I: Codification of the samples (continued) 
 
Set No. Material A Material B Material C 
16 QUIN/2006/144 QUIN/2006/074 QUIN/2006/169 
  QUIN/2006/087 QUIN/2006/088 
  QUIN/2006/095  
17 QUIN/2006/121 QUIN/2006/136 QUIN/2006/015 
  QUIN/2006/060 QUIN/2006/160 
  QUIN/2006/167  
18 QUIN/2006/046 QUIN/2006/146 QUIN/2006/098 
  QUIN/2006/094 QUIN/2006/022 
  QUIN/2006/113  
19 QUIN/2006/027 QUIN/2006/122 QUIN/2006/143 
  QUIN/2006/149 QUIN/2006/111 
  QUIN/2006/013  
20 QUIN/2006/156 QUIN/2006/081 QUIN/2006/067 
  QUIN/2006/059 QUIN/2006/072 
  QUIN/2006/009  
21 QUIN/2006/099 QUIN/2006/151 QUIN/2006/085 
  QUIN/2006/154 QUIN/2006/127 
  QUIN/2006/071  
22 QUIN/2006/079 QUIN/2006/175 QUIN/2006/011 
  QUIN/2006/033 QUIN/2006/038 
  QUIN/2006/018  
23 QUIN/2006/051 QUIN/2006/076 QUIN/2006/164 
  QUIN/2006/168 QUIN/2006/031 
  QUIN/2006/101  
24 QUIN/2006/030 QUIN/2006/172 QUIN/2006/132 
  QUIN/2006/077 QUIN/2006/050 
  QUIN/2006/120  
25 QUIN/2006/007 QUIN/2006/047 QUIN/2006/112 
  QUIN/2006/174 QUIN/2006/176 
  QUIN/2006/008  
26 QUIN/2006/002 QUIN/2006/097 QUIN/2006/140 
  QUIN/2006/062 QUIN/2006/110 
  QUIN/2006/152  
27 QUIN/2006/064 QUIN/2006/157 QUIN/2006/032 
  QUIN/2006/057 QUIN/2006/108 
  QUIN/2006/023  
28 QUIN/2006/118 QUIN/2006/103 QUIN/2006/128 
  QUIN/2006/134 QUIN/2006/129 
  QUIN/2006/083  
29 QUIN/2006/039 QUIN/2006/142 QUIN/2006/070 
  QUIN/2006/069 QUIN/2006/036 
  QUIN/2006/163  
30 QUIN/2006/096 QUIN/2006/075 QUIN/2006/035 
  QUIN/2006/010 QUIN/2006/005 
  QUIN/2006/055  
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APPENDIX IIa: Statistical evaluation of homogeneity data of material B for ciprofloxacin 
 
 Ciprofloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 30.8 24.8 
2 25.4 29.5 
3 32.7 21.9 
4 24.4 25.0 
5 29.3 28.9 
6 26.9 32.3 
7 33.7 34.0 
8* 30.5 98.4 
9 29.0 32.0 
10 31.0 25.1 
Grand mean 28.7 
Cochran’s test   
C 0.477 
Ccrit 0.638 
C < Ccrit? NO OUTLIERS 
Target sd (σp) Horwitz: 6.31 
san2 13.4 
ssam2 0 
σall2 3.6 
critical 20.3 
ssam2 < critical? ACCEPTED 
* One of the duplicate results is very high due to a low signal of the internal standard. This duplicate 
was indicated as an outlier by the Cochran’s test. The presented results of the Cochran’s test were 
calculated after elimination of this outlying duplicate. 
 
 
No flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid or sarafloxacin was detected in 
the samples (< 5 µg/kg).  
 
san2 = estimate of analytical variance 
ssam2 = estimate of sampling variance 
σall2 = allowable sampling variance 
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APPENDIX IIb: Statistical evaluation of homogeneity data of material B for enrofloxacin 
 
 Enrofloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 65.0 56.2 
2 54.6 57.6 
3 59.6 51.2 
4 52.1 54.3 
5 57.1 58.1 
6 58.5 58.3 
7 66.1 64.4 
8* 60.5 198.8 
9 59.9 59.4 
10 62.3 56.7 
Grand mean 58.4 
Cochran’s test   
C 0.395 
Ccrit 0.638 
C < Ccrit? NO OUTLIERS 
Target sd (σp) Horwitz: 12.9 
san2 10.9 
ssam2 6.7 
σall2 14.9 
critical 39.0 
ssam2 < critical? ACCEPTED 
* One of the duplicate results is very high due to a low signal of the internal standard. This duplicate 
was indicated as an outlier by the Cochran’s test. The presented results of the Cochran’s test were 
calculated after elimination of this outlying duplicate. 
 
No flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid or sarafloxacin was detected in 
the samples (< 5 µg/kg).  
 
san2 = estimate of analytical variance 
ssam2 = estimate of sampling variance 
σall2 = allowable sampling variance 
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APPENDIX IIc: Statistical evaluation of homogeneity data of material B for danofloxacin 
 
 Danofloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 223 187 
2 165 167 
3 197 174 
4 162 155 
5 178 203 
6 196 194 
7 226 231 
8* 227 678 
9 225 204 
10 205 208 
Grand mean 195 
Cochran’s test   
C 0.449 
Ccrit 0.638 
C < Ccrit? NO OUTLIERS 
Target sd (σp) Horwitz: 39.8 
san2 167 
ssam2 415 
σall2 165 
critical 478 
ssam2 < critical? ACCEPTED 
* One of the duplicate results is very high due to a low signal of the internal standard. This duplicate 
was indicated as an outlier by the Cochran’s test. The presented results of the Cochran’s test were 
calculated after elimination of this outlying duplicate. 
 
No flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid or sarafloxacin was detected in 
the samples (< 5 µg/kg).  
 
san2 = estimate of analytical variance 
ssam2 = estimate of sampling variance 
σall2 = allowable sampling variance 
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APPENDIX IId: Statistical evaluation of homogeneity data of material B for difloxacin 
 
 Difloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 300 229 
2 207 203 
3 253 210 
4 196 193 
5 206 252 
6 224 258 
7 275 269 
8* 272 815 
9 256 205 
10 273 214 
Grand mean 234 
Cochran’s test   
C 0.314 
Ccrit 0.638 
C < Ccrit? NO OUTLIERS 
Target sd (σp) Horwitz: 46.7 
san2 899 
ssam2 167 
σall2 196 
critical 1277 
ssam2 < critical? ACCEPTED 
* One of the duplicate results is very high due to a low signal of the internal standard. This duplicate 
was indicated as an outlier by the Cochran’s test. The presented results of the Cochran’s test were 
calculated after elimination of this outlying duplicate. 
 
No flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid or sarafloxacin was detected in 
the samples (< 5 µg/kg).  
 
san2 = estimate of analytical variance 
ssam2 = estimate of sampling variance 
σall2 = allowable sampling variance 
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APPENDIX IIIa: Statistical evaluation of homogeneity data of material C for ciprofloxacin 
 
 Ciprofloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 36.3 36.3 
2 36.4 36.3 
3 39.9 37.6 
4 36.8 37.8 
5 32.3 32.5 
6 31.8 32.8 
7 26.7 30.3 
8 29.8 35.3 
9 32.5 30.1 
10 34.9 35.3 
Grand mean 34.1 
Cochran’s test   
C 0.527 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target sd (σp) Horwitz: 7.5 
san2 2.8 
ssam2 8.7 
σall2 5.1 
critical 12.3 
ssam2 < critical? ACCEPTED 
 
No flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid or sarafloxacin was detected in 
the samples (< 5 µg/kg).  
 
san2 = estimate of analytical variance 
ssam2 = estimate of sampling variance 
σall2 = allowable sampling variance 
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APPENDIX IIIb: Statistical evaluation of homogeneity data of material C for enrofloxacin 
 
 Enrofloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 80.0 73.7 
2 75.0 78.4 
3 79.6 71.4 
4 76.1 73.6 
5 71.9 75.2 
6 66.1 83.7 
7 73.7 69.7 
8 69.5 73.6 
9 76.9 69.0 
10 73.2 70.1 
Grand mean 74.0 
Cochran’s test   
C 0.562 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target sd (σp) Horwitz: 16.3 
san2 27.3 
ssam2 0 
σall2 23.9 
critical 72.4 
ssam2 < critical? ACCEPTED 
 
No flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid or sarafloxacin was detected in 
the samples (< 5 µg/kg).  
 
san2 = estimate of analytical variance 
ssam2 = estimate of sampling variance 
σall2 = allowable sampling variance 
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APPENDIX IIIc: Statistical evaluation of homogeneity data of material C for danofloxacin 
 
 Danofloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 130 127 
2 132 147 
3 155 123 
4 134 122 
5 119 130 
6 143 146 
7 121 116 
8 123 140 
9 109 105 
10 133 119 
Grand mean 129 
Cochran’s test   
C 0.510 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target sd (σp) Horwitz: 28.0 
san2 103 
ssam2 80 
σall2 72 
critical 240 
ssam2 < critical? ACCEPTED 
 
No flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid or sarafloxacin was detected in 
the samples (< 5 µg/kg).  
 
san2 = estimate of analytical variance 
ssam2 = estimate of sampling variance 
σall2 = allowable sampling variance 
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APPENDIX IIId: Statistical evaluation of homogeneity data of material C for difloxacin 
 
 Difloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 133 142 
2 143 152 
3 126 147 
4 156 141 
5 136 152 
6 127 124 
7 135 135 
8 115 148 
9 143 117 
10 150 117 
Grand mean 137 
Cochran’s test   
C 0.279 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target sd (σp) Horwitz: 29.6 
san2 194 
ssam2 0 
σall2 79 
critical 343 
ssam2 < critical? ACCEPTED 
 
No flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid or sarafloxacin was detected in 
the samples (< 5 µg/kg).  
 
san2 = estimate of analytical variance 
ssam2 = estimate of sampling variance 
σall2 = allowable sampling variance 
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APPENDIX IVa: Statistical evaluation of stability data of ciprofloxacin  
 
Statistical evaluation for ciprofloxacin in material B 
Date of analysis Time 
(days) 
Average amount  
(µg/kg) 
n Pooled st. dev 
(µg/kg) 
t tcrit t < tcrit 
12-16-2005 0 28.7 18     
03-15-2006 88 30.5 6 5.1 0.75 2.08 ACCEPTED 
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Statistical evaluation for ciprofloxacin in material C 
Date of analysis Time 
(days) 
Average amount 
(µg/kg) 
n Pooled st. dev 
(µg/kg) 
t tcrit t < tcrit 
12-16-2005 0 34.1 20     
03-15-2006 88 38.9 6 6.1 1.69 2.06 ACCEPTED 
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APPENDIX IVb: Statistical evaluation of stability data of enrofloxacin  
 
Statistical evaluation for enrofloxacin in material B 
Date of analysis Time 
(days) 
Average amount 
(µg/kg) 
n Pooled st. dev 
(µg/kg) 
t tcrit t < tcrit 
12-16-2005 0 58.4 18     
03-15-2006 88 53.3 6 6.4 1.69 2.08 ACCEPTED 
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Statistical evaluation for enrofloxacin in material C 
Date of analysis Time 
(days) 
Average amount 
(µg/kg) 
n Pooled st. dev 
(µg/kg) 
t tcrit t < tcrit 
12-16-2005 0 74.0 20     
03-15-2006 88 78.9 6 6.8 1.54 2.06 ACCEPTED 
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APPENDIX IVc: Statistical evaluation of stability data of danofloxacin  
 
Statistical evaluation for danofloxacin in material B 
Date of analysis Time 
(days) 
Average amount 
(µg/kg) 
n Pooled st. dev 
(µg/kg) 
t tcrit t < tcrit 
12-16-2005 0 195 18     
03-15-2006 88 167 6 30.7 1.90 2.08 ACCEPTED 
0.0
50.0
100.0
150.0
200.0
250.0
0 10 20 30 40 50 60 70 80 90
t ime (days)
ca
lc
ul
at
ed
 a
ve
ra
ge
 a
m
ou
nt
 (µ
g/
kg
)
 
Statistical evaluation for danofloxacin in material C 
Date of analysis Time 
(days) 
Average amount 
(µg/kg) 
n Pooled st. dev 
(µg/kg) 
t tcrit t < tcrit 
12-16-2005 0 129 20     
03-15-2006 88 99 6 17.1 3.76 2.06 NOT ACCEPTED 
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APPENDIX IVd: Statistical evaluation of stability data of difloxacin  
 
Statistical evaluation for difloxacin in material B 
Date of analysis Time 
(days) 
Average amount 
(µg/kg) 
n Pooled st. dev 
(µg/kg) 
t tcrit t < tcrit 
12-16-2005 0 234 18     
03-15-2006 88 229 6 14.7 0.79 2.08 ACCEPTED 
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Statistical evaluation for difloxacin in material C 
Date of analysis Time 
(days) 
Average amount 
(µg/kg) 
n Pooled st. dev 
(µg/kg) 
t tcrit t < tcrit 
12-16-2005 0 137 20     
03-15-2006 88 138 6 12.8 0.09 2.06 ACCEPTED 
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APPENDIX V: Overview of the applied methods 
Lab code Extraction Sample purification Internal 
standard 
Detection 
method 
Quinolones not analysed for 2002/657/EC
? 
Lab1 PBS-EDTA buffer / ACN Dilution, ultrafiltration (30kD) - LC-MS/MS  Yes 
Lab2 Phosphoric acid, ACN, 
MeOH 
Partial evaporation, SPE (Oasis® HLB), etulion 
MeOH, evaporation, reconstitution 
- LC-FLU-UV marbofloxacin Yes 
Lab3 Phosphate buffer (pH=7.4) SPE (C18), elution TFA in ACN, evaporation, 
reconstitution 
- LC-FLU difloxacin, marbofloxacin, 
sarafloxacin 
NM 
Lab4 Water Filtration 0.45 µm, ultrafiltration (30 kD) cincophen, 
lomefloxacin 
LC-MS/MS - Yes 
Lab5   - LC-FLU danofloxacin, difloxacin, 
marbofloxacin, nalidixic acid, 
norfloxacin, sarafloxacin 
 
Lab7 Acetonitrile SPE (SDB-RPS) cincophen, 
lomefloxacin 
LC-MS/MS difloxacin, sarafloxacin Yes 
Lab9 Phosphate buffer (pH=6.5) SPE (C18), elution acetic MeOH,  
evaporation, reconstitution 
- LC-FLU nalidixic acid Yes 
Lab10 Acetic acid in ethanol Evaporation of solvent, reconstitution, centrifugation - LC-FLU - Yes 
Lab11 Acedic ACN SPE (C18), elution ACN, evaporation, reconstitution - LC-MS/MS -  
Lab12 Glycine / HCl SPE (OASIS® HLB), etution MeOH 
evaporation, reconstitution 
d8-ciprofloxacin 
d5-enrofloxacin 
LC-MS/MS  Yes 
Lab13 ACN Evaporation, reconstitution, SPE (SDB-RPS), 
elution ACN/NH4OH, evaporation, reconstitution, 
filtration 0.45 µm 
d5-norfloxacin LC-MS/MS - Yes 
Lab14 Trichloroacetic acid (5%) Filtration 0.45 µm - LC-FLU - Yes 
Lab15 Water SPE (C18), elution: 1% TFA in ACN 
evaporation, reconstitution 
quinine / 
sarafloxacin1)  
LC-MS/MS - Yes 
Lab16 Trichloricacetic acid (5%) Filtration 0.45 µm d5-norfloxacin LC-MS/MS - Yes 
Lab17 Phosphate buffer (pH=7.4) SPE (DSC-C18), elution MeOH/NH4OH, 
evaporation, reconstitution 
- LC-FLU marbofloxacin, nalidixic acid, 
norfloxacin 
Yes 
NM = not mentioned 
1) The screening analysis showed that no sarafloxacin was in the sample. Because of structure equivalency, sarafloxacin was used as the internal standard for the CIP, ENR, DAN and DIF. 
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APPENDIX VI: Overview of method characteristics as reported by the participants  
 
  CIP ENR DAN DIF 
Lab 
code 
Validation / 
accreditation 
CCα 
(µg/kg) 
CCß 
(µg/kg) 
CCα 
(µg/kg) 
CCß 
(µg/kg) 
CCα 
(µg/kg) 
CCß 
(µg/kg) 
CCα 
(µg/kg) 
CCß 
(µg/kg) 
Lab1 Yes (not for DIF, SAR, 
MAR) / No 
112 125 110 120 120 139   
Lab3 Yes /Yes         
Lab4 Yes / No 117 141 115 141 252 310 333 383 
Lab5 Yes / Yes 1 2 1 2     
Lab6          
Lab7 Yes / Yes  <0.25  <0.25  <50   
Lab10 Yes / Yes 115 130 115 130 230 260 345 390 
Lab12 Yes / Yes 113 123 116 134 233 260 334 351 
Lab13 Yes / Yes 111 136 114 142 228 288 362 503 
Lab14 Yes / Yes   119 140 223 245 327 350 
Lab15 Yes / Yes 119.1 137.7 117.7 136.3 262.2 316.5 458.1 516.9 
Lab16 In progress / No 115 130 115 130 234 269 352 404 
Lab17 Yes / Yes 59.4 69.1 65.0 79.3     
 
 
  CIP ENR DAN DIF 
Lab 
code 
Validation  according to 
2002/657/ accreditation 
LoD 
(µg/kg) 
LoQ 
(µg/kg) 
LoD 
(µg/kg) 
LoQ 
(µg/kg) 
LoD 
(µg/kg) 
LoQ 
(µg/kg) 
LoD 
(µg/kg) 
LoQ 
(µg/kg) 
Lab2 Yes (validation not 
according to 
2002/657/EC / Yes 
10 20 10 20 5 10 10 20 
Lab3 Yes / Yes 0.25 0.40 0.51 0.83 0.25 0.40   
Lab4 Yes / No 5 10 5 10 5 10 5 10 
Lab6          
Lab7 Yes / Yes 1.91 6.38 0.87 2.98 0.87 2.90   
Lab9 Yes/ CIP+ENR 2 3 1 2     
Lab10 Yes / Yes  6  6  2  10 
Lab11 No / Yes 0.02 0.05 0.02 0.05 0.02 0.05 0.02 0.05 
Lab14 Yes / Yes   5 15 7 20 6 25 
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APPENDIX VII: The result for the analysis of ciprofloxacin in poultry muscle (material B) 
 
Ciprofloxacin 
Assigned value: 33.2 µg/kg 
Uncertainty of assigned value: 3.1 µg/kg 
Target standard deviation (Horwitz, Thompson): 7.3 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6 Average  sr LRs  za’-score HORRAT 
Lab1 12 11 13 11 13 13 12.2 0.91 1.00 -2.65 0.14
Lab2 38.3 40.8 36.8 38.2 39.2 37.2 38.4 1.43 1.45 0.66 0.20
Lab3 19.7 18.3 19.4 19.3 20.3 18.0 19.2 1.10 1.10 -1.76 0.15
Lab4 35 35 32 32 30 30 32.3 0.00 2.52 -0.10 0.34
Lab5 24.9 27.4 26.7 30.2 25.8 28.8 27.3 2.14 2.14 -0.74 0.29
Lab7 26 26 29 24 26 27 26.3 2.08 2.08 -0.86 0.29
Lab9 34.5 34.2 35.1 34.5 31.0 32.4 33.6 0.63 1.73 0.06 0.24
Lab10 34.1 32.9 31.4 32.6 32.0 31.1 32.4 0.78 1.16 -0.10 0.16
Lab11 47.32 46.29 3.40* 9.20* 50.49 49.27 48.3 2.46 24.38 1.91 3.32
Lab12 41.3 42.1 45.6 39.5 42.2 42.9 42.3 2.53 2.53 1.15 0.35
Lab13 52.14 54.44 55.71 55.24 59.76 59.01 56.1 1.01 3.17 2.89 0.43
Lab14 7 8 9 8 6 5 7.2 0.71 1.61 -3.28 0.22
Lab15 34.1 38.0 38.0 42.7 40.4 42.7 39.3 2.66 3.45 0.78 0.47
Lab16 69.1 68.6 64.7 73.0 61.0 72.1 68.1 5.66 5.66 4.40 0.78
Lab17 31.8 29.8 33.1 28.9 27.0 26.9 29.6 1.90 2.65 -0.45 0.36
Bold values indicate a questionable or unsatisfactory performance (|za’-score|>2 or HORRAT>1) 
* This value was indicated as an outlier and was therefore not included in the statistical evaluation regarding the accuracy. 
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Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za’-score Figure c: Graphical representation of HORRAT  
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APPENDIX VIII: The result for the analysis of ciprofloxacin in poultry muscle (material C) 
 
Ciprofloxacin 
Assigned value: 38.1 µg/kg 
Uncertainty of assigned value: 12.6 µg/kg 
Target standard deviation (Horwitz, Thompson): 3.2 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average  sr LRs  za’-score HORRAT 
Lab1 12 12 14 14 13.0 0.00 1.41 -2.79 0.17
Lab2 35.6 42.1 43.2 42.3 40.8 2.68 3.35 0.30 0.40
Lab3 18.6 20.1 26.8 25.1 22.7 0.93 4.71 -1.72 0.56
Lab4 36 31 27 40 33.5 5.69 5.69 -0.51 0.68
Lab5 25.1 31.8 27.2 31.4 28.9 3.23 3.23 -1.02 0.39
Lab7 26 30 33 33 30.5 1.63 3.72 -0.84 0.44
Lab9 42.9 39.1 37.5 40.9 40.1 2.08 2.08 0.23 0.25
Lab10 36.1 42.0 37.8 40.0 39.0 2.57 2.57 0.10 0.31
Lab11 61.61 53.06 54.08 62.22 57.7 4.82 4.82 2.19 0.58
Lab12 47.2 46.3 42.4 49.4 46.3 2.88 2.88 0.92 0.34
Lab13 61.11 64.09 55.81 60.32 60.3 2.21 3.57 2.48 0.43
Lab14 9 10 9 9 9.3 0.41 0.46 -3.21 0.05
Lab15 44.9 46.0 41.5 49.1 45.4 3.14 3.14 0.81 0.37
Lab16 84.2 69.9 62.8 74.8 72.9 7.62 7.94 3.88 0.95
Lab17 34.5 37.4 28.6 30.2 32.7 1.35 4.73 -0.60 0.56
Bold values indicate a questionable or unsatisfactory performance (|za’-score|>2) 
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APPENDIX VIII: The result for the analysis of ciprofloxacin in poultry muscle (material C) (continued) 
 
 
Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za’-score Figure c: Graphical representation of HORRAT  
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APPENDIX IX: The result for the analysis of enrofloxacin in poultry muscle (material B) 
 
Enrofloxacin 
Assigned value: 68.1 µg/kg 
Uncertainty of assigned value: 5.7 µg/kg 
Target standard deviation (Horwitz, Thompson): 15.0 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6 Average  sr LRs  za’-score HORRAT 
Lab1 20 19 20 19 19 20 19.5 0.71 0.71 -3.05 0.05
Lab2 89.1 91.6 73.1 80.5 77.6 76.4 81.4 3.23 8.09 0.90 0.55
Lab3 72.1 72.5 71.0 67.0 63.1 61.5 67.9 1.77 5.25 0.03 0.35
Lab4 54 59 53 53 51 51 53.5 2.04 3.14 -0.88 0.21
Lab5 37.9 41.8 41.5 47.0 39.1 43.7 41.8 3.33 3.33 -1.63 0.22
Lab7 28 24 30 17 28 29 26.0 5.57 5.57 -2.64 0.38
Lab9 63.2 66.0 65.8 66.9 65.9 68.6 66.1 1.65 1.78 -0.08 0.12
Lab10 78.2 73.6 78.1 73.1 73.4 72.0 74.7 2.83 2.83 0.47 0.19
Lab11 86.50 96.50 4.76* 90.91 94.03 88.27 91.2 4.71 25.33 1.44 1.71
Lab12 59.1 57.4 64.5 63.3 60.5 59.0 60.6 1.05 3.02 -0.43 0.20
Lab13 72.69 70.57 71.40 73.21 74.77 71.62 72.4 1.72 1.72 0.32 0.12
Lab14 97 110 109 102 79 70 94.5 7.06 18.05 1.73 1.22
Lab15 72.7 78.6 75.9 90.3 74.8 87.6 80.0 8.23 8.23 0.81 0.56
Lab16 164 131 153 135 180 206 161.5 18.66 30.35 6.01 2.05
Lab17 65.4 66.7 65.7 63.2 58.9 61.2 63.5 0.71 3.28 -0.24 0.22
Bold values indicate a questionable or unsatisfactory performance (|za’-score|>2 or HORRAT>1) 
* This value was indicated as an outlier and was therefore not included in the statistical evaluation regarding the accuracy. 
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APPENDIX IX: The result for the analysis of enrofloxacin in poultry muscle (material B) (continued) 
 
 
Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za’-score Figure c: Graphical representation of HORRAT  
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APPENDIX X: The result for the analysis of enrofloxacin in poultry muscle (material C) 
 
Enrofloxacin 
Assigned value: 81.9 µg/kg 
Uncertainty of assigned value: 5.6 µg/kg 
Target standard deviation (Horwitz, Thompson): 18.1 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average  sr LRs  za’-score HORRAT 
Lab1 23 22 27 27 24.8 0.50 3.20 -3.03 0.18
Lab2 80.4 88.4 88.4 87.2 86.1 3.30 3.35 0.22 0.19
Lab3 65.2 70.0 80.6 83.4 74.8 2.27 10.31 -0.38 0.57
Lab4 71 77 69 73 72.5 2.94 2.97 -0.50 0.16
Lab5 39.6 50.1 47.1 54.6 47.9 5.27 5.65 -1.81 0.31
Lab7 37 41 49 38 41.3 4.78 4.78 -2.16 0.27
Lab9 83 80 78 80 80.1 1.71 2.05 -0.10 0.11
Lab10 90.3 90.9 93.2 88.7 90.8 1.85 1.85 0.47 0.10
Lab11 109.75 108.79 111.25 113.88 110.9 1.14 2.47 1.54 0.14
Lab12 74.1 73.5 82.7 82.2 78.1 0.32 6.12 -0.20 0.34
Lab13 85.24 93.74 83.02 88.45 87.6 4.12 4.12 0.30 0.23
Lab14 114 128 140 128 127.5 7.53 10.62 2.41 0.59
Lab15 98.2 112.2 101.2 106.9 104.6 6.17 6.17 1.20 0.34
Lab16 199 196 274 281 237.5 3.11 56.61 8.24 3.14
Lab17 79.9 83.4 60.4 70.9 73.7 4.52 11.76 -0.44 0.65
Bold values indicate a questionable or unsatisfactory performance (|za’-score|>2 or HORRAT>1) 
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APPENDIX X: The result for the analysis of enrofloxacin in poultry muscle (material C) (continued) 
 
 
Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za’-score Figure c: Graphical representation of HORRAT  
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APPENDIX XI: The result for the analysis of the sum of ciprofloxacin and enrofloxacin in poultry muscle (material B) 
 
Ciprofloxacin + enrofloxacin 
Assigned value: 101.4 µg/kg 
Uncertainty of assigned value: 7.4 µg/kg 
Target standard deviation (Horwitz, Thompson): 22.3 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6 Average  sr LRs  za’-score HORRAT 
Lab1 32 30 33 30 32 33 31.7 1.53 1.53 -2.97 0.07
Lab2 127.4 132.4 109.9 118.7 116.8 113.6 119.8 4.33 9.28 0.78 0.42
Lab3 91.8 90.8 90.4 86.3 83.4 79.5 87.0 2.35 5.32 -0.61 0.24
Lab4 89 94 85 85 81 81 85.8 2.04 5.49 -0.66 0.25
Lab5 62.8 69.2 68.2 77.2 64.9 72.5 69.1 5.47 5.47 -1.37 0.25
Lab7 54 50 59 41 54 56 52.3 7.57 7.57 -2.09 0.34
Lab9 97.7 100.2 100.9 101.4 96.9 101.0 99.7 1.97 1.97 -0.07 0.09
Lab10 112.3 106.5 109.5 105.7 105.4 103.1 107.1 2.98 3.36 0.24 0.15
Lab11 133.8 142.8 8.16* 100.08* 144.5 137.5 139.7 37.81 56.18 1.63 1.71
Lab12 100.4 99.5 110.1 102.8 102.7 101.9 102.9 3.02 3.92 0.06 0.18
Lab13 124.8 125.0 127.1 128.5 134.5 130.6 128.4 1.69 4.05 1.15 0.18
Lab14 104 118 118 110 85 75 101.7 7.75 19.60 0.01 0.88
Lab15 106.8 116.6 113.9 133.0 115.2 130.3 119.3 10.71 10.71 0.76 0.48
Lab16 233.1 199.6 217.7 208.0 241.0 278.1 229.6 20.79 29.88 5.46 1.35
Lab17 97.2 96.5 98.8 92.1 85.9 88.1 93.1 2.89 5.71 -0.35 0.26
Bold values indicate a questionable or unsatisfactory performance (|za’-score|>2 or HORRAT>1) 
* This value was indicated as an outlier and was therefore not included in the statistical evaluation regarding the accuracy. 
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APPENDIX XI: The result for the analysis of the sum of ciprofloxacin and enrofloxacin in poultry 
muscle (material B) (continued) 
 
 
Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za’-score Figure c: Graphical representation of HORRAT  
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APPENDIX XII: The result for the analysis of the sum of ciprofloxacin and enrofloxacin in poultry muscle (material C) 
 
Ciprofloxacin + enrofloxacin 
Assigned value: 122 µg/kg 
Uncertainty of assigned value: 7.3 µg/kg 
Target standard deviation (Horwitz, Thompson): 26.8 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average  sr LRs  za-score HORRAT 
Lab1 35 34 41 41 37.8 0.50 4.61 -3.15 0.17
Lab2 116.0 130.5 131.6 129.5 126.9 5.98 6.67 0.17 0.25
Lab3 83.8 90.1 107.4 108.5 97.5 2.61 14.96 -0.92 0.56
Lab4 107 108 96 113 106.0 6.95 6.95 -0.61 0.26
Lab5 64.7 81.9 74.3 86.0 76.7 8.49 8.49 -1.70 0.32
Lab7 63 71 82 71 71.8 5.55 7.78 -1.88 0.29
Lab9 125.8 118.8 115.1 121.2 120.2 3.79 3.97 -0.08 0.15
Lab10 126.4 132.9 131.0 128.7 129.8 2.81 2.81 0.28 0.10
Lab11 171.4 161.9 165.3 176.1 168.7 5.87 5.87 1.73 0.22
Lab12 121.3 119.8 125.1 131.6 124.5 2.72 5.84 0.08 0.22
Lab13 146.4 157.8 138.8 148.8 147.9 6.20 7.32 0.96 0.27
Lab14 123 138 149 137 136.8 7.84 10.43 0.54 0.39
Lab15 143.1 158.2 142.7 156.0 150.0 8.21 8.21 1.03 0.31
Lab16 283.2 265.9 336.8 355.8 310.4 10.49 51.27 7.01 1.91
Lab17 114.4 120.8 89.0 101.1 106.3 5.59 16.43 -0.59 0.61
Bold values indicate a questionable or unsatisfactory performance (|za-score|>2 or HORRAT>1) 
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APPENDIX XII: The result for the analysis of the sum of ciprofloxacin and enrofloxacin in poultry 
muscle (material C) (continued) 
 
 
Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za-score Figure c: Graphical representation of HORRAT  
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APPENDIX XIII: The result for the analysis of danofloxacin in poultry muscle (material B) 
 
Danofloxacin 
Assigned value: 192 µg/kg 
Uncertainty of assigned value: 11 µg/kg 
Target standard deviation (Horwitz, Thompson): 39.3 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6 Average  sr LRs  za-score HORRAT 
Lab1 19 18 22 18 21 21 19.8 1.68 1.73 -4.37 0.05
Lab2 192.6 198.8 183.3 201.2 196.5 187.4 193.3 8.58 8.58 0.04 0.23
Lab3 137.7 148.8 170.8 159.7 139.9 145.9 150.5 6.86 13.69 -1.05 0.36
Lab4 161 173 176 159 163 160 165.3 8.58 8.58 -0.67 0.23
Lab7 158 154 154 122 148 148 147.3 13.17 13.17 -1.13 0.35
Lab9 192.0 192.0 194.0 190.0 191.0 200.0 193.2 4.02 4.02 0.04 0.11
Lab10 207.2 229.5 203.3 230.8 203.5 231.9 217.7 18.53 18.53 0.67 0.49
Lab11 214.65 225.45 0.81* 12.90* 231.59 235.60 226.8 6.82 127.27 0.90 3.34
Lab12 200.0 197.8 195.2 199.5 209.6 199.7 200.3 4.50 4.99 0.22 0.13
Lab13 173.64 185.39 164.40 173.12 188.98 176.50 177.0 7.85 9.19 -0.37 0.24
Lab14 365 396 408 370 280 239 343.0 26.10 74.75 3.85 1.96
Lab15 168.2 157.3 168.5 181.6 168.1 175.1 169.8 7.52 8.28 -0.55 0.22
Lab16 460.0 377.0 459.0 417.0 385.0 540.0 439.7 73.80 73.80 6.31 1.94
Lab17 204.8 229.1 219.9 203.9 183.7 187.4 204.8 11.97 18.87 0.34 0.50
Bold values indicate a questionable or unsatisfactory performance (|za-score|>2 or HORRAT>1) 
* This value was indicated as outliers and was therefore not included in the statistical evaluation regarding the accuracy. 
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APPENDIX XIII: The result for the analysis of danofloxacin in poultry muscle (material B) (continued) 
 
 
Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za-score Figure c: Graphical representation of HORRAT  
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APPENDIX XIV: The result for the analysis of danofloxacin in poultry muscle (material C) 
 
Danofloxacin 
Assigned value: 118 µg/kg 
Uncertainty of assigned value: 9.3 µg/kg 
Target standard deviation (Horwitz, Thompson): 26.0 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average  sr LRs  za’-score HORRAT 
Lab1 8 8 11 12 9.8 0.50 2.50 -3.92 0.10
Lab2 88.7 115.3 120.5 120.3 111.2 10.86 15.11 -0.25 0.58
Lab3 80.7 87.5 97.1 101.0 91.6 3.20 10.81 -0.96 0.42
Lab4 107 110 84 95 99.0 4.65 13.83 -0.69 0.53
Lab7 88 84 110 110 98.0 1.63 17.01 -0.72 0.66
Lab9 123.0 117.0 113.0 122.0 118.8 4.42 4.42 0.03 0.17
Lab10 123.4 145.3 128.0 145.0 135.4 11.32 11.32 0.63 0.44
Lab11 114.17 149.94 147.93 149.65 140.4 14.62 15.71 0.81 0.61
Lab12 129.6 126.8 130.2 132.4 129.8 1.45 2.42 0.43 0.09
Lab13 112.88 120.31 112.74 114.87 115.2 3.16 3.16 -0.10 0.12
Lab14 191 216 247 216 217.5 16.26 22.89 3.61 0.88
Lab15 94.5 106.4 88.2 102.8 98.0 7.69 7.69 -0.73 0.30
Lab16 276.0 231.0 284.0 295.0 271.5 18.91 28.75 5.57 1.11
Lab17 124.6 132.6 88.3 111.1 114.2 9.86 21.59 -0.14 0.83
Bold values indicate a questionable or unsatisfactory performance (|za’-score|>2 or HORRAT>1) 
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APPENDIX XIV: The result for the analysis of danofloxacin in poultry muscle (material C) (continued) 
 
 
Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za’-score Figure c: Graphical representation of HORRAT  
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APPENDIX XV: The result for the analysis of difloxacin in poultry muscle (material B) 
 
Difloxacin 
Assigned value: 299 µg/kg 
Uncertainty of assigned value: 22 µg/kg 
Target standard deviation (Horwitz, Thompson): 57.4 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6 Average  sr LRs  za’-score HORRAT 
Lab1 81 81 84 88 91 87 85.3 2.31 4.36 -3.49 0.08
Lab2 293.5 292.6 280.7 281.6 283.6 284.3 286.1 0.59 6.24 -0.21 0.11
Lab4 243 252 237 240 243 220 239.2 10.16 10.77 -0.98 0.19
Lab9 274 294 297 296 294 306 293.5 9.53 10.78 -0.09 0.19
Lab10 297.3 280.6 278.7 284.2 281.0 286.2 284.7 7.49 7.49 -0.24 0.13
Lab11 561.31 544.10 512.56 495.18 515.77 506.88 522.6 10.62 27.36 3.64 0.48
Lab12 322.5 282.6 409.9 373.7 407.1 376.2 362.0 25.36 54.52 1.02 0.95
Lab13 245.94 235.37 224.16 246.28 255.98 246.84 242.4 10.68 11.18 -0.93 0.19
Lab14 356 426 405 388 296 265 356.0 32.02 69.25 0.93 1.21
Lab15 277.8 241.3 276.4 344.0 317.6 343.4 300.1 33.08 43.39 0.01 0.76
Lab16 489 470 612 519 486 456 505.3 40.64 59.66 3.36 1.04
Lab17 256.5 263.1 246.3 249.8 231.0 235.5 247.0 3.56 13.54 -0.85 0.24
Bold values indicate a questionable or unsatisfactory performance (|za’-score|>2 or HORRAT>1) 
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APPENDIX XV: The result for the analysis of difloxacin in poultry muscle (material B) (continued) 
 
 
Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za’-score Figure c: Graphical representation of HORRAT  
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APPENDIX XVI: The result for the analysis of difloxacin in poultry muscle (material C) 
 
Difloxacin 
Assigned value: 188 µg/kg 
Uncertainty of assigned value: 20  µg/kg 
Target standard deviation (Horwitz, Thompson): 38.6 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average  sr LRs  za’-score HORRAT 
Lab1 51 50 57 62 55.0 2.55 6.61 -3.05 0.17
Lab2 167.1 169.8 173.1 173.2 170.8 1.10 3.41 -0.39 0.09
Lab4 147 139 114 152 138.0 15.85 15.85 -1.14 0.41
Lab9 186 177 170 181 178.5 5.80 5.90 -0.21 0.15
Lab10 185.6 181.2 184.1 179.2 182.5 2.69 2.69 -0.12 0.07
Lab11 318.47 353.29 346.83 362.46 345.3 15.58 17.25 3.63 0.45
Lab12 203.7 166.5 231.0 240.1 210.3 15.63 37.35 0.52 0.97
Lab13 156.54 172.08 147.17 157.94 158.4 7.72 9.94 -0.67 0.26
Lab14 208 249 278 247 245.5 20.98 28.25 1.33 0.73
Lab15 173.1 204.1 153.8 185.9 179.2 18.22 18.49 -0.19 0.48
Lab16 331 324 287 278 305.0 4.65 31.99 2.70 0.83
Lab17 154.8 161.1 119.1 133.7 142.2 6.49 22.78 -1.05 0.59
Bold values indicate a questionable or unsatisfactory performance (|za’-score|>2) 
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APPENDIX XVI: The result for the analysis of difloxacin in poultry muscle (material C) (continued) 
 
 
Figure a: Graphical representation of the reported results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure b: Graphical representation of za’-score Figure c: Graphical representation of HORRAT  
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APPENDIX XVII: The calculation of the laboratory performance score 
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Accuracy 
 
Reproducibility 
Laboratory 
performance 
Code pos. neg. Material B Material C Material B Material C Material B Material C Material B Material C score (%) score (%) score (%) 
Lab1 - - 0 / 1 0 / 1 0 / 1 0 / 1 0 / 1 0 / 1 0 / 1 0 / 1 0 100 50 
Lab2 - - 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 100 100 100 
Lab3 - - 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 - - 100 100 100 
Lab4 - - 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 100 100 100 
Lab5 - - 1 / 1 1 / 1 1 / 1 1 / 1 - - - - 100 100 100 
Lab7 - - 1 / 1 1 / 1 0 / 1 0 / 1 1 / 1 1 / 1 - - 67 100 83 
Lab9 - - 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 100 100 100 
Lab10 - - 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 100 100 100 
Lab11 - - 1 / 0 0 / 1 1 / 0 1 / 1 1 / 0 1 / 1 0 / 1 0 / 1 63 63 63 
Lab12 - - 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 100 100 100 
Lab13 - - 0 / 1 0 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 75 100 88 
Lab14 - - 0 / 1 0 / 1 1 / 0 0 / 1 0 / 0 0 / 1 1 / 0 1 / 1 38 62 50 
Lab15 - - 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 100 100 100 
Lab16 - - 0 / 1 0 / 1 0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 0 / 1 0 38 19 
Lab17 - - 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 100 100 100 
 
 
